Teva slashing workforce amid restructuring

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv: TEVA) disclosed details of its restructuring plan, which includes reducing global headcount by 14,000 jobs, or 26%, to 39,000 over the next two years. Teva expects the cuts, which will come from all locations and functions, to reduce

Read the full 451 word article

How to gain access

Continue reading with a
two-week free trial.